Researchers at Baylor College of Medicine terminated a clinical trial testing the drug semagacestat for the treatment of Alzheimer's disease after patients in the treatment and placebo groups showed comparably worsening cognitive scores. The team's study also reported in the New England Journal of Medicine that semagacestat was linked to increased adverse events, including skin cancer and infection.

Related Summaries